BioInvent
Ideon Science and Technology Park
Sölvegatan 41
Lund
S-223 70
Tel: 46-46-286-8550
Fax: 46-46-211-0806
Website: http://www.bioinvent.com/
Email: info@bioinvent.com
311 articles about BioInvent
-
BioInvent’s Bi-1206 Antibody To Enter Collaborative Phase 1/2 Trial Funded And Conducted By Cancer Research UK, CRT And LLR
1/20/2015
-
BioInvent Interim Report 1 January – 30 September 2014
10/23/2014
-
BioInvent Receives Another Milestone Payment From Bayer In Connection With Start Of A Phase I Trial
9/11/2014
-
BioInvent Interim Report 1 January – 30 June 2014
7/24/2014
-
BioInvent Has Received Milestones From Bayer Pharma S.A. And Servier
7/7/2014
-
BioInvent Granted U.S. Patent For BI-505 And Apoptosis-Inducing ICAM-1 Antibodies
6/24/2014
-
BioInvent Interim Report 1 January – 31 March 2014
5/6/2014
-
Change In The Number Of Shares And Votes In BioInvent
4/30/2014
-
BioInvent Annual General Meeting
4/24/2014
-
Notice Of Annual General Meeting In BioInvent
3/24/2014
-
BioInvent: Annual Report 2013
3/21/2014
-
BioInvent Financial Statement 1 January – 31 December 2013
2/20/2014
-
BioInvent Granted US Patent for the F.I.R.S.T.™ Antibody Screening Technology
11/11/2013
-
BioInvent Interim Report 1 January – 30 September 2013
10/24/2013
-
BioInvent and Bayer AG Extend and Broaden Collaboration for the Discovery and Development of Therapeutic Antibodies
10/14/2013
-
BioInvent Interim Report 1 January – 30 June 2013
7/25/2013
-
BioInvent Extends Collaboration for the Discovery and Development of Therapeutic Antibodies With Mitsubishi Tanabe Pharma Corporation
7/2/2013
-
Resolutions at BioInvent's Extraordinary General Meeting
6/19/2013
-
BioInvent Implements a Rights Issue of Approx. SEK 22 Million
6/19/2013
-
BioInvent Recruits Michael Oredsson as New CEO
5/24/2013